Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology?

Grants

Funding Acknowledgements

B J L has received honoraria and travel grants from Sanofi-Aventis. He is also conducting research funded by a research grant to the University of Melbourne from Boehringer Ingelheim. S A has received honoraria and travel grants from Sanofi-Aventis, MSD, GSK, Servier, Boehringer Ingelheim, Medtronic and AZ/BMS.